Figure 2.

Univariate logistic regression analysis for atrial angiotensin‐converting enzyme 2 (ACE2) mRNA expression. Forest plot showing odds ratio (OR) and 95% confidence interval (CI) derived from univariate logistic regression analysing the risk of increased atrial ACE2 mRNA expression (>0.5478) for multiple clinical variables. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro brain natriuretic peptide; TIA, transient ischaemic attack. ^#Requirement of symptoms and LVEF <40% or elevated NT‐proBNP levels and either left ventricular hypertrophy (left ventricular mass index ≥115 g/m² for male, ≥95 g/m² for female patients), left atrial enlargement (left atrial volume index >34 mL/m²), or diastolic dysfunction. ^¶>300 pg/mL for patients without atrial fibrillation, >900 pg/mL for patients with atrial fibrillation. ^§Glomerular filtration rate <60 mL/min.